Jasmin Tiro to Mass Screening
This is a "connection" page, showing publications Jasmin Tiro has written about Mass Screening.
Connection Strength
1.887
-
Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2005 Dec; 14(12):2855-61.
Score: 0.165
-
Validation of scales measuring attitudes and norms related to mammography screening in women veterans. Health Psychol. 2005 Nov; 24(6):555-66.
Score: 0.164
-
Long-term Mammography Adherence among Uninsured Women Enrolled in the Breast Screening and Patient Navigation (BSPAN) Program. Cancer Epidemiol Biomarkers Prev. 2022 01; 31(1):77-84.
Score: 0.125
-
Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2022 08; 20(8):1795-1802.e2.
Score: 0.119
-
Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening: A Review. JAMA Otolaryngol Head Neck Surg. 2020 07 01; 146(7):656-664.
Score: 0.113
-
Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. Int J Cancer. 2019 03 15; 144(6):1460-1473.
Score: 0.102
-
Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result. J Womens Health (Larchmt). 2019 03; 28(3):384-392.
Score: 0.102
-
Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. Am J Gastroenterol. 2018 05; 113(5):746-754.
Score: 0.096
-
Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system. Cancer. 2016 Feb 01; 122(3):456-63.
Score: 0.082
-
Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst. 2015 Jun; 107(6):djv120.
Score: 0.079
-
Interventions to promote repeat breast cancer screening with mammography: a systematic review and meta-analysis. J Natl Cancer Inst. 2010 Jul 21; 102(14):1023-39.
Score: 0.057
-
Construct validity and invariance of four factors associated with colorectal cancer screening across gender, race, and prior screening. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2231-7.
Score: 0.050
-
Reliability and validity of a questionnaire to measure colorectal cancer screening behaviors: does mode of survey administration matter? Cancer Epidemiol Biomarkers Prev. 2008 Apr; 17(4):758-67.
Score: 0.049
-
Promoting regular mammography screening I. A systematic assessment of validity in a randomized trial. J Natl Cancer Inst. 2008 Mar 05; 100(5):333-46.
Score: 0.048
-
Promoting regular mammography screening II. Results from a randomized controlled trial in US women veterans. J Natl Cancer Inst. 2008 Mar 05; 100(5):347-58.
Score: 0.048
-
Gaps in care across the cancer screening continuum for cervical, colorectal, and lung cancers. J Natl Cancer Inst. 2025 Dec 01; 117(12):2556-2570.
Score: 0.041
-
Cervical cancer screening rates in females living with HIV at three healthcare settings in the United States, 2010-2019. Cancer Causes Control. 2025 Mar; 36(3):275-284.
Score: 0.038
-
Some methodologic lessons learned from cancer screening research. Cancer. 2004 Sep 01; 101(5 Suppl):1131-45.
Score: 0.038
-
Factors associated with timely colposcopy following an abnormal cervical cancer test result. Prev Med. 2022 11; 164:107307.
Score: 0.033
-
Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a U.S. healthcare system: The STEP trial. Contemp Clin Trials. 2022 11; 122:106960.
Score: 0.033
-
Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings. Cancer Med. 2023 02; 12(3):3705-3717.
Score: 0.033
-
Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1517-1520.
Score: 0.033
-
Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1521-1531.
Score: 0.033
-
Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2022 01; 154:106871.
Score: 0.031
-
De-implementation of cervical cancer screening before age 21. Prev Med. 2021 12; 153:106815.
Score: 0.031
-
Anal cancer screening among women with HIV: provider experiences and system-level challenges. AIDS Care. 2022 02; 34(2):220-226.
Score: 0.030
-
Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial. JAMA Netw Open. 2019 11 01; 2(11):e1914729.
Score: 0.027
-
Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. JAMA. 2017 09 05; 318(9):806-815.
Score: 0.023
-
An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017 04; 65(4):1196-1205.
Score: 0.022
-
Was the drop in mammography rates in 2005 associated with the drop in hormone therapy use? Cancer. 2011 Dec 15; 117(24):5450-60.
Score: 0.015
-
Too much of a good thing? Physician practices and patient willingness for less frequent pap test screening intervals. Med Care. 2010 Mar; 48(3):249-59.
Score: 0.014
-
Reported drop in mammography : is this cause for concern? Cancer. 2007 Jun 15; 109(12):2405-9.
Score: 0.011